Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)
Primary Purpose
Human Influenza
Status
Active
Phase
Phase 1
Locations
Australia
Study Type
Interventional
Intervention
UFluA 20 µg each antigen/dose
UFluA 60 µg each antigen/dose
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Human Influenza focused on measuring universal, universal influenza vaccine, phase 1, randomized, double-blind, placebo
Eligibility Criteria
Inclusion Criteria:
- Male and female adults (18-45 years of age, inclusive) at the Screening visit.
- Body mass index of 18.5-32.0 kg/m^2 (inclusive) at the Screening visit.
- Healthy, based on medical history (no chronic disease, no chronic therapy, no ongoing acute condition within four weeks prior to dosing as per PI [or designee] discretion), normal PE (no clinically significant findings in the opinion of the PI [or designee]), no clinically significant findings on screening electrocardiogram (ECG) and laboratory assessments in the opinion of the PI [or designee].
- Females must not be pregnant or trying to become pregnant.
- Both male and female subjects agree to acceptable forms of birth control. Male subjects must not donate sperm for the duration of the study.
Exclusion Criteria:
- Enrollment in an interventional study and/or receipt of any investigational product within 30 days prior to screening visit or during the study.
- Currently breastfeeding or planning to be breastfeeding during the study.
- History of severe allergic reaction(s) or anaphylaxis.
- Known allergy to any component of the vaccine.
- History of any known immunodeficiency or immunocompromising condition that could impact response to administration of the investigational product (e.g., leukemia, lymphoma, malignancy, renal failure, asplenia, diabetes mellitus, alcoholic cirrhosis).
- Receipt or anticipated receipt of blood products from 180 days prior to the Screening visit through 90 days following administration of IP.
- Positive laboratory evidence of current infection at the Screening visit with HIV 1 and 2 (as determined by HIV 1/2 antibody test), HCV (as determined by HCV antibody test), or HBV [as determined by HBV surface antigen (HBsAg) test]. Note: positive anti-HCV antibody result along with a negative HCV PCR result would not be exclusionary.
- Any clinically significant abnormalities in rhythm, conduction, or morphology of the resting 12-lead electrocardiogram (ECG) based on the PI's (or designee's) review of tracing results at the Screening visit. [Non-pathologic sinus bradycardia (heart rate must be >40 beats per minute) is allowed].
- Receipt or anticipated receipt of the seasonal influenza vaccination from up to 90 days prior to dosing and through up to 30 days following the last dose administration.
- Receipt or anticipated receipt of any COVID-19 vaccine from up to 14 days prior to dosing and through up to 30 days following the last dose administration.
- Receipt or anticipated receipt of any other vaccines from up to 90 days prior to dosing and through up to 30 days following last dose administration of investigational product.
- Receipt or anticipated receipt of systemic immunomodulatory agents or other immune modifying drugs (including systemic corticosteroids exceeding 20 mg/day for ≥14 days) and antineoplastic agents from up to six months prior to dosing and through the entire duration of the study.
- Planned medical procedure(s) that will impact study compliance during the follow-up period.
- Positive urine drug screen test or any evidence of ongoing drug abuse or dependence (including alcohol), or recent history over the past five years of treatment for alcohol or drug abuse.
- Planning to donate bone marrow, blood, and blood products from the time of screening until 3 months after receiving the last dose.
- Have a tattoo/scar/birthmark or any other skin condition affecting the deltoid area that may interfere with injection site assessments.
- History of H. pylori infection or documented iron deficiency within the past five years.
- An opinion of the PI (or designee) that it would not be in the best interest of the subject to allow participation in the study.
Sites / Locations
- Northern Beaches Clinical Research
- Linear Clinical Research
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm Type
Active Comparator
Active Comparator
Placebo Comparator
Active Comparator
Active Comparator
Placebo Comparator
Arm Label
Cohort 1, 1A
Cohort 1, 1B
Cohort 1, 1C
Cohort 2, 2A
Cohort 2, 2B
Cohort 2, 2C
Arm Description
Low dose (Day 1) plus placebo (Day 22)
Low dose (Day 1) plus low dose (Day 22)
Placebo (Day 1) plus Placebo (Day 22)
High dose (Day 1) plus placebo (Day 22)
High dose (Day 1) plus high dose (Day 22)
Placebo (Day 1) plus Placebo (Day 22)
Outcomes
Primary Outcome Measures
Safety of the UFluA vaccine following one of four dose schedules as evaluated through adverse events (AEs), serious adverse events (SAEs), adverse events of special interest (AESIs) and medically attended adverse events (MAAEs).
Incidence of AEs up to 4 weeks after last dose. Incidence of SAEs up to 48 weeks of study follow-up. Incidence of AESIs up to 48 weeks of study follow-up. Incidence of MAAEs up to 48 weeks of study follow-up.
Local and systemic reactogenicity of UFluA vaccination following one of four dose schedules.
Incidences of local reactogenicity events up to 7 days after each vaccination. Incidences of systemic reactogenicity events up to 7 days after each vaccination.
Secondary Outcome Measures
Anti-H. pylori ferritin immune response to UFluA vaccination.
Anti-H-pylori ferritin antibody titers at multiple timepoints up to 4 weeks after the last vaccination.
Anti-human ferritin immune response to UFluA vaccination.
Anti-human ferritin antibody levels at multiple timepoints up to 4 weeks after the last vaccination.
Humoral immune response to A1 influenza antigen following UFluA vaccination.
Peak anti-A1 stem binding antibody titers (as measured by an immunoassay) at multiple timepoints up to 4 weeks after the last vaccination.
Humoral immune response to A2 influenza antigen following UFluA vaccination.
Peak anti-A2 stem binding antibody titers (as measured by an immunoassay) at multiple timepoints up to 4 weeks after the last vaccination.
Full Information
NCT ID
NCT05155319
First Posted
November 25, 2021
Last Updated
August 9, 2023
Sponsor
Emergent BioSolutions
1. Study Identification
Unique Protocol Identification Number
NCT05155319
Brief Title
Universal Influenza A Vaccine in Healthy Adults
Acronym
EBS-UFV-001
Official Title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study Evaluating Safety and Immunogenicity of Influenza A Hemagglutinin Stabilized Stem Nanoparticle Vaccine Candidate in Healthy Adults
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
December 1, 2021 (Actual)
Primary Completion Date
October 13, 2023 (Anticipated)
Study Completion Date
April 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Emergent BioSolutions
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The goal of this Phase 1, single- center, randomized, double blind, placebo-controlled dose-escalation study is to evaluate the safety, tolerability and immunogenicity of UFluA vaccine candidate at two dose levels and two schedules in healthy adult (18-45-year-old, inclusive) male and non-pregnant female subjects.
Detailed Description
A total of 60 healthy adult subjects will be enrolled in the study and followed through Day 337 (i.e., up to 48 weeks after first dose). Subjects will be enrolled into two study cohorts to receive either a low dose (Cohort 1; n=30 receives) or high dose (Cohort 2; n=30) of adjuvanted UFluA or placebo (saline), administered intramuscularly (IM) as single dose or as two doses (administered 21 days apart).
UFluA is comprised of DP-UFluA (1:1 A1-ssnp and A2-ssnp antigens) and contains aluminum hydroxide and CpG adjuvants.
Primary Objective:
To evaluate safety and tolerability of UFluA IM administration in healthy adults.
Secondary Objectives:
To assess anti-hemagglutinin humoral immune responses in healthy adults who receive UFluA. To assess ferritin (Helicobacter pylori and human) immune response in healthy adults who receive UFluA.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Human Influenza
Keywords
universal, universal influenza vaccine, phase 1, randomized, double-blind, placebo
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Cohort 1, 1A
Arm Type
Active Comparator
Arm Description
Low dose (Day 1) plus placebo (Day 22)
Arm Title
Cohort 1, 1B
Arm Type
Active Comparator
Arm Description
Low dose (Day 1) plus low dose (Day 22)
Arm Title
Cohort 1, 1C
Arm Type
Placebo Comparator
Arm Description
Placebo (Day 1) plus Placebo (Day 22)
Arm Title
Cohort 2, 2A
Arm Type
Active Comparator
Arm Description
High dose (Day 1) plus placebo (Day 22)
Arm Title
Cohort 2, 2B
Arm Type
Active Comparator
Arm Description
High dose (Day 1) plus high dose (Day 22)
Arm Title
Cohort 2, 2C
Arm Type
Placebo Comparator
Arm Description
Placebo (Day 1) plus Placebo (Day 22)
Intervention Type
Biological
Intervention Name(s)
UFluA 20 µg each antigen/dose
Intervention Description
Low dose
Intervention Type
Biological
Intervention Name(s)
UFluA 60 µg each antigen/dose
Intervention Description
High Dose
Intervention Type
Biological
Intervention Name(s)
Placebo
Intervention Description
Placebo
Primary Outcome Measure Information:
Title
Safety of the UFluA vaccine following one of four dose schedules as evaluated through adverse events (AEs), serious adverse events (SAEs), adverse events of special interest (AESIs) and medically attended adverse events (MAAEs).
Description
Incidence of AEs up to 4 weeks after last dose. Incidence of SAEs up to 48 weeks of study follow-up. Incidence of AESIs up to 48 weeks of study follow-up. Incidence of MAAEs up to 48 weeks of study follow-up.
Time Frame
48 weeks
Title
Local and systemic reactogenicity of UFluA vaccination following one of four dose schedules.
Description
Incidences of local reactogenicity events up to 7 days after each vaccination. Incidences of systemic reactogenicity events up to 7 days after each vaccination.
Time Frame
seven days after each vaccination
Secondary Outcome Measure Information:
Title
Anti-H. pylori ferritin immune response to UFluA vaccination.
Description
Anti-H-pylori ferritin antibody titers at multiple timepoints up to 4 weeks after the last vaccination.
Time Frame
up to 4 weeks after the last vaccination.
Title
Anti-human ferritin immune response to UFluA vaccination.
Description
Anti-human ferritin antibody levels at multiple timepoints up to 4 weeks after the last vaccination.
Time Frame
up to 4 weeks after the last vaccination.
Title
Humoral immune response to A1 influenza antigen following UFluA vaccination.
Description
Peak anti-A1 stem binding antibody titers (as measured by an immunoassay) at multiple timepoints up to 4 weeks after the last vaccination.
Time Frame
up to 4 weeks after the last vaccination.
Title
Humoral immune response to A2 influenza antigen following UFluA vaccination.
Description
Peak anti-A2 stem binding antibody titers (as measured by an immunoassay) at multiple timepoints up to 4 weeks after the last vaccination.
Time Frame
up to 4 weeks after the last vaccination.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Male and female adults (18-45 years of age, inclusive) at the Screening visit.
Body mass index of 18.5-32.0 kg/m^2 (inclusive) at the Screening visit.
Healthy, based on medical history (no chronic disease, no chronic therapy, no ongoing acute condition within four weeks prior to dosing as per PI [or designee] discretion), normal PE (no clinically significant findings in the opinion of the PI [or designee]), no clinically significant findings on screening electrocardiogram (ECG) and laboratory assessments in the opinion of the PI [or designee].
Females must not be pregnant or trying to become pregnant.
Both male and female subjects agree to acceptable forms of birth control. Male subjects must not donate sperm for the duration of the study.
Exclusion Criteria:
Enrollment in an interventional study and/or receipt of any investigational product within 30 days prior to screening visit or during the study.
Currently breastfeeding or planning to be breastfeeding during the study.
History of severe allergic reaction(s) or anaphylaxis.
Known allergy to any component of the vaccine.
History of any known immunodeficiency or immunocompromising condition that could impact response to administration of the investigational product (e.g., leukemia, lymphoma, malignancy, renal failure, asplenia, diabetes mellitus, alcoholic cirrhosis).
Receipt or anticipated receipt of blood products from 180 days prior to the Screening visit through 90 days following administration of IP.
Positive laboratory evidence of current infection at the Screening visit with HIV 1 and 2 (as determined by HIV 1/2 antibody test), HCV (as determined by HCV antibody test), or HBV [as determined by HBV surface antigen (HBsAg) test]. Note: positive anti-HCV antibody result along with a negative HCV PCR result would not be exclusionary.
Any clinically significant abnormalities in rhythm, conduction, or morphology of the resting 12-lead electrocardiogram (ECG) based on the PI's (or designee's) review of tracing results at the Screening visit. [Non-pathologic sinus bradycardia (heart rate must be >40 beats per minute) is allowed].
Receipt or anticipated receipt of the seasonal influenza vaccination from up to 90 days prior to dosing and through up to 30 days following the last dose administration.
Receipt or anticipated receipt of any COVID-19 vaccine from up to 14 days prior to dosing and through up to 30 days following the last dose administration.
Receipt or anticipated receipt of any other vaccines from up to 90 days prior to dosing and through up to 30 days following last dose administration of investigational product.
Receipt or anticipated receipt of systemic immunomodulatory agents or other immune modifying drugs (including systemic corticosteroids exceeding 20 mg/day for ≥14 days) and antineoplastic agents from up to six months prior to dosing and through the entire duration of the study.
Planned medical procedure(s) that will impact study compliance during the follow-up period.
Positive urine drug screen test or any evidence of ongoing drug abuse or dependence (including alcohol), or recent history over the past five years of treatment for alcohol or drug abuse.
Planning to donate bone marrow, blood, and blood products from the time of screening until 3 months after receiving the last dose.
Have a tattoo/scar/birthmark or any other skin condition affecting the deltoid area that may interfere with injection site assessments.
History of H. pylori infection or documented iron deficiency within the past five years.
An opinion of the PI (or designee) that it would not be in the best interest of the subject to allow participation in the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James McCarthy, MD
Organizational Affiliation
Emergent BioSolutions
Official's Role
Study Director
Facility Information:
Facility Name
Northern Beaches Clinical Research
City
Brookvale
State/Province
New South Wales
ZIP/Postal Code
2100
Country
Australia
Facility Name
Linear Clinical Research
City
Nedlands
State/Province
Western Australia
ZIP/Postal Code
6009
Country
Australia
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Universal Influenza A Vaccine in Healthy Adults
We'll reach out to this number within 24 hrs